MDM2 PROTAC | Clinical Trials Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

1,725 results for “MDM2 PROTAC”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

First Human Trial of Targeting MDM2/MDMX PET Imaging

3 participants · First posted Jun 5, 2024

Effects of Systematic Proprioceptive-tactile Stimulation With Use of the Protac MyFit®

240 participants · First posted Nov 22, 2019

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

21 participants · First posted Aug 31, 2018

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

45 participants · First posted Dec 16, 2024

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

28 participants · First posted Oct 31, 2018

A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

68 participants · First posted Mar 28, 2014

Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma

14 participants · First posted Oct 20, 2015

Active, not recruiting

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

42 participants · First posted Jun 5, 2014

Active, not recruiting

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

33 participants · First posted Jul 13, 2022

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

35 participants · First posted Jul 17, 2019

Page 1 of 127